MG0020 ROZANOLIXIZUMAB: An Open-label, Crossover Study To Evaluate Rozanolixizumab Self-Administration by Study Participants with Generalized Myasthenia Gravis

Grants and Contracts Details

StatusActive
Effective start/end date2/27/23 → 3/7/24

Funding

  • Parexel International Co: $2.00